AlphAIalphai — Financial news for AI agents
tradingview.comAUG 182 min read

TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing

Amgen will terminate its research collaboration and license agreement with TScan Therapeutics, according to an SEC filing. The companies had been working together on developing novel cancer therapies.

Original reporting
tradingview.com
Published Aug 18, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$TCRX · $AMGN
Relevance
5/10
alphai data visualization · based on tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

Deal termination can change TScan’s expected funding, development timeline, and licensing revenue prospects, and may prompt reassessment of pipeline valuation.

02

Market read

This is a company-specific contract termination headline that can move small-cap biotech sentiment, but the provided text lacks financial specifics.

03

What to watch

Traders will need the SEC filing details: termination effective date, any milestone clawbacks, ongoing rights to existing IP, and whether Amgen retains or returns licenses.

Relevance 5/10Novelty 4/10Timing: after-hours/SEC filing reported on 2026-08-18

Background

The title indicates an SEC filing about Amgen terminating a research collaboration and license agreement with TScan Therapeutics.

Market effects

Sector

Signals potential churn in biotech collaboration licensing, which can affect sentiment toward small-cap biotech dealmaking.

Regional

No clear regional spillover indicated by the provided text.

Global

Limited based on the absence of deal size, geography, or broader regulatory context.

Counterpoint

What could challenge this read

If the collaboration was underperforming or non-core, termination could be viewed as freeing resources for TScan’s internal programs rather than a fundamental setback.

Key entities

  • company
    TScan Therapeutics

    Subject of the SEC-filing news, with Amgen terminating a research collaboration and license agreement.

  • company
    Amgen

    Counterparty expected to terminate the collaboration and license agreement with TScan.

Read at source← All news

Related articles

AUG 31
$AMGNMed

Trump Announces New Drug Pricing Deals With Nine Manufacturers

President Trump announced new voluntary drug pricing agreements with nine pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Merck, to lower U.S. prescription drug prices. The deals, part of the TrumpRx platform, aim to align prices with those in other wealthy nations. Companies receive tariff relief in exchange for participation. Critics note limited impact on patient costs and lack of public contract details.

vinnews.com2 min
AUG 31
$AMGNHighAI 9/10

Amgen's Repatha Cuts Death Risk 20% In High-Risk Patients Without Prior Heart Attack Or Stroke

Amgen (AMGN) reported that its drug Repatha reduced death risk by 20% in high-risk patients without prior heart attack or stroke, per Phase 3 trial data. The study, involving 12,000+ patients, also showed reductions in cardiovascular events. Repatha is approved in 75 countries and used by 9M patients globally. AMGN stock closed at $432.42 on Friday, up 0.95% in pre-market trading.

rttnews.com2 min
AUG 31
$AMGNHighAI 9/10

AMGN Looks 18.3% Overvalued on GF Value™ as Dividend Sustainabil

Amgen (AMGN) reported Phase 3 trial results showing its drug Repatha reduced mortality risk by 20%. The company offers a 2.3% dividend yield with a 44% payout ratio and a 7.1% 3-year growth rate. AMGN's stock trades 18.3% above its GF Value™ of $365.50, with a GF Score™ of 79. Insider activity shows $29.3M in sales, while institutional gurus show a slight net trimming trend.

gurufocus.com3 min
AUG 31
$AMGNMedAI 8/10

AMGN Looks 18.3% Overvalued on GF Value™

Amgen (AMGN) reported that its drug Repatha reduced mortality risk in high-risk patients, per a clinical trial. The company offers a 2.3% dividend yield with a 44% payout ratio and a 7.1% 3-year dividend growth rate. AMGN's stock trades 18.3% above its GF Value™, with a GF Score™ of 79. Insider sales totaled $29.3M over the past year, while institutional investors show mixed sentiment.

gurufocus.com3 min